Unlikely to what had been observed in murine models, it has been shown that HR-MDS patient samples specifically undergo cell death in response to venetoclax even when harboring mutations in ASXL1, RUNX1, TP53 or EZH2 (228). Here, RUNX1 is linked to myelodysplastic syndrome.